Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.

By J. Mazières, S. Peters, B. Lepage, A. Cortot, F. Barlesi, M. Beau-Faller, B. Besse, H. Blons, A. Mansuet-Lupo, T. Urban and 9 more. Journal of Clinical Oncology, 2013

664 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/a6d7061a10d70fbb3f3465fc74ee9cf14be06a2a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. A. Thai
2. D. Camidge
3. A. Drilon
4. A. Lusque
5. R. Rosell
6. S. Ou
7. L. Mhanna
8. Laura Mezquita

Citations in the corpus

• Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry (2019, methodology): “We previously conducted registry studies on targeted therapies for NSCLC with ROS1, HER2, BRAF and RET alterations [14-18].”